The German CLL Study Group conducted a randomized, double-blind, placebo-controlled phase III trial with 363 patients with asymptomatic, treatment-naïve Binet stage A CLL at increased risk of ...

Lori A. Leslie, MD, and Hoshiyuki Iida, APN, provide an overview of chronic lymphocytic leukemia and the risk stratification process. Lori A. Leslie, MD: Hello, and welcome to CURE Expert Connections® ...

CURE looks back on some of the most important stories in the chronic lymphocytic leukemia space from 2023. In honor of September being blood cancer awareness month, we took a look at five noteworthy ...

Matching-adjusted indirect comparison methodology was utilized to compare ibrutinib arms across the ALPINE and ELEVATE-RR trials. In each study, ibrutinib was used as the comparator for a ...

Improvements seen in overall survival, progression-free survival, and cancer-specific survival. HealthDay News — For patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

A diagnosis of chronic lymphocytic leukemia (CLL) can be overwhelming, but advances in cancer research, including targeted therapies, have paved the way for more precise treatments. Brandon Blackstock ...

Personalized exercise guidance is needed for people living with Chronic Lymphocytic Leukemia (CLL), the most common type of blood cancer, according to a new study led by the University of Surrey. The ...